RedHill Biopharma Ltd. (RDHL) Form 6-K — Oct 21, 2026

$RDHLForm 6-KFiled Oct 21, 2026, 7:00 AM ET0001178913-26-004808Original filing

RedHill Biopharma has regained full ex-North America rights to RHB-102 after Hyloris Pharmaceuticals mutually terminated their License & Development Agreement, effective October 15, 2026. Hyloris paid RedHill a one-time break-up fee of $200,000. RHB-102 is a once-daily, proprietary extended-release oral formulation of ondansetron, a 5-HT3 antagonist. RedHill now holds worldwide rights and continues late-stage development for oncology support and GI indications, including GLP-1/GIP-associated GI intolerance.

Key figures

Break up fee usd: 200000
License agreement date: February 24, 2025
Termination effective date: October 15, 2026

AI analysis

Red flags2 · Pro

The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.

Upgrade to Pro · $49/mo billed annually

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.